The Consortium to Establish a Registry for Alzheimer's Disease (Cerad). Part I. Clinical and neuropsychological assesment of Alzheimer's disease

Dados Bibliográficos

ID23319352
AutoresJ C Moms (Washington University in St. Louis), Albert Heyman (Duke University), Richard C Mohs (0000-0002-3765-6287, Icahn School of Medicine at Mount Sinai), James P Hughes (0000-0001-5034-3157, University of Washington), Gerald van Belle (0000-0002-8552-158X, University of Washington), Gerda G Fillenbaum (0000-0002-3075-5223, Duke University), G Fillenbaum, E David Mellits (Johns Hopkins University), C Clark (0000-0002-2727-6651), Christopher M Clark (0000-0002-4716-4155, Duke University)
Ano1989
Volume39
Fascículo9
Páginas1159-1159
Data de publicação1989-09-01
Peer ReviewedSim
Open AccessSim
TipoARTICLE
PeriódicoNeurology (JOURNAL)
Identificadores do periódicoISSN: 0028-3878 • E-ISSN: 1526-632X
EditoraOvid Technologies (Wolters Kluwer Health) (PUBLISHER)
DOI10.1212/wnl.39.9.1159
PMID2771064
OpenAlexW2158766477
IdiomaEN
Citações recebidas123

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) has developed brief, comprehensive, and reliable batteries of clinical and neuropsychological tests for assessment of patients with the clinical diagnosis of Alzheimer's disease (AD). We administered these batteries in a standardized manner to more than 350 subjects with a diagnosis of AD and 275 control subjects who were enrolled in a nationwide registry by a consortium of 16 university medical centers. The tests selected for this study measured the primary cognitive manifestations of AD across a range of severity of the disorder, and discriminated between normal subjects and those with mild and moderate dementia. The batteries also detected deterioration of language, memory, praxis, and general intellectual status in subjects returning for reassessment 1 year later. Interrater and test-retest reliabilities were substantial. Long-term observations of this cohort are in progress in an effort to validate the clinical and neuropsychological assessments and to confirm the diagnosis by postmortem examinations. Although information on validation is limited thus far, the CERAD batteries appear to fill a need for a standardized, easily administered, and reliable instrument for evaluating persons with AD in multicenter research studies as well as in clinical practice.

Alzheimer's disease · Cognition · Cohort · Dementia · Disease · Neuropsychological assessment · Neuropsychology · Pathology · Psychiatry · Dementia and Cognitive Impairment Research · Medicine · Gerontology · Pediatrics